

Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P9FDDDB8DA34EN.html>

Date: March 2022

Pages: 105

Price: US\$ 2,000.00 (Single User License)

ID: P9FDDDB8DA34EN

Abstracts

Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.

Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. PWS is due to lack of several genes on one of an individual's two chromosome 15's. In the majority of cases, there is a deletion. In remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15's from the mother (uniparental disomy).

Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action

(MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 6, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products

which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication

therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Prader-Willi Syndrome (PWS) - Overview
- Prader-Willi Syndrome (PWS) - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Prader-Willi Syndrome (PWS) - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development
 - 9 Meters Biopharma Inc
 - Aardvark Therapeutics Inc
 - Altamira Therapeutics Ltd
 - Benuvia Therapeutics Inc
 - Beryl Therapeutics Inc
 - Biomind Labs Inc
 - Bioprojet SCR
 - Carmot Therapeutics Inc
 - ConSynance Therapeutics Inc
 - Ferring International Center SA
 - GLWL Research Inc
 - Helsinn Group
 - Inversago Pharma Inc
 - Lipidio Pharmaceuticals Inc
 - Lumos Pharma Inc
 - Neuracle Science Co Ltd
 - Neuren Pharmaceuticals Ltd
 - Notitia Biotechnologies Co
 - OptiNose Inc
 - OT4B
 - Saniona AB
 - Soleno Therapeutics Inc

Taysha Gene Therapies Inc
Tonix Pharmaceuticals Holding Corp
Prader-Willi Syndrome (PWS) - Drug Profiles
(metoprolol + tesofensine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
betahistine dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic for Prader Willi Syndrome - Drug Profile
Product Description
Mechanism Of Action
Bittera - Drug Profile
Product Description
Mechanism Of Action
BMND-04 - Drug Profile
Product Description
Mechanism Of Action
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
History of Events
carbetocin LA - Drug Profile
Product Description
Mechanism Of Action
History of Events
CSTI-500 - Drug Profile
Product Description
Mechanism Of Action
diazoxide choline CR - Drug Profile
Product Description
Mechanism Of Action
History of Events
GDD-3898 - Drug Profile
Product Description
Mechanism Of Action
GLWL-01 - Drug Profile

Product Description
Mechanism Of Action
History of Events
HM-04 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HU-671 - Drug Profile
Product Description
Mechanism Of Action
ibutamoren mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
INV-202 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MRI-1867 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NM-136 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NNZ-2591 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NS-200 - Drug Profile
Product Description
Mechanism Of Action
oxytocin - Drug Profile
Product Description
Mechanism Of Action
oxytocin - Drug Profile
Product Description
Mechanism Of Action

History of Events

oxytocin - Drug Profile

Product Description

Mechanism Of Action

History of Events

oxytocin - Drug Profile

Product Description

Mechanism Of Action

History of Events

pitolisant hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit SMCHD1 for Prader Willi Syndrome - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Target Incretin for Prader-Willi syndrome - Drug Profile

Product Description

Mechanism Of Action

History of Events

TSHA-116 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Prader-Willi Syndrome (PWS) - Dormant Projects

Prader-Willi Syndrome (PWS) - Discontinued Products

Prader-Willi Syndrome (PWS) - Product Development Milestones

Featured News & Press Releases

Mar 09, 2022: Running for research - Prader-Willi Syndrome to fund multi-center study of DCCR in early phase Prader-Willi syndrome

Mar 03, 2022: Tonix Pharmaceuticals announces FDA Orphan-Drug Designation for TNX-2900 for the treatment of Prader-Willi Syndrome

Feb 28, 2022: Tonix Pharmaceuticals announces research agreement with the French National Institute of Health and Medical Research (Inserm) to study the mechanism of oxytocin-mediated improvement of eating behaviors in Prader-Willi Mice

Feb 03, 2022: Aardvark starts enrolment in three Phase II trials of TAS2R agonist

Jan 24, 2022: Soleno Therapeutics provides regulatory update on DCCR for the treatment of Prader-Willi syndrome

Dec 28, 2021: Saniona initiates phase 2b clinical trial of tesomet for Prader-Willi syndrome

Oct 18, 2021: Saniona completes submission of manufacturing data for Tesomet capsules to U.S. FDA

Oct 11, 2021: US patent to 2034 granted for Neuren's NNZ-2591 in autism

Sep 17, 2021: adMare Portfolio Company, Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 Blocker

Sep 08, 2021: Soleno Therapeutics announces positive data showing continued significant improvements in symptoms of PWS following one year treatment with DCCR

Sep 07, 2021: Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 blocker

Sep 03, 2021: FDA grants Orphan Drug Designation for NNZ-2591 to treat Prader-Willi syndrome

Jul 26, 2021: Saniona receives U.S. FDA orphan drug designation for Tesomet in hypothalamic obesity

Jul 22, 2021: Radius Health announces plans for global Prader-Willi syndrome pivotal study

Jul 06, 2021: Soleno Therapeutics provides regulatory update on DCCR for the treatment of Prader-Willi syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Prader-Willi Syndrome (PWS), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Prader-Willi Syndrome (PWS) - Pipeline by 9 Meters Biopharma Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Aardvark Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Altamira Therapeutics Ltd, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Benuvia Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Beryl Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Biomind Labs Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Bioprojet SCR, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Carmot Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by ConSynance Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center SA, 2022
Prader-Willi Syndrome (PWS) - Pipeline by GLWL Research Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Helsinn Group, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Inversago Pharma Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Lipidio Pharmaceuticals Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Lumos Pharma Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Neuracle Science Co Ltd, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Neuren Pharmaceuticals Ltd, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Notitia Biotechnologies Co, 2022
Prader-Willi Syndrome (PWS) - Pipeline by OptiNose Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by OT4B, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Soleno Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Taysha Gene Therapies Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Prader-Willi Syndrome (PWS) - Dormant Projects, 2022

Prader-Willi Syndrome (PWS) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Prader-Willi Syndrome (PWS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P9FDDDB8DA34EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P9FDDDB8DA34EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

